Lupus & antiphospholipid syndrome
Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in daily clinical practice: A prospective study of 125 patients in India
Authors' conclusion
SLE-DAS demonstrated superior sensitivity, granularity, and remission alignment compared to SLEDAI-2K, supporting its adoption as a primary clinical index in diverse real-world lupus practices.
Study context
- Population
- Systemic Lupus Erythematosus (SLE) patients meeting 2012 SLICC and/or 2019 ACR/EULAR criteria at an Indian Rheumatology Clinic, followed for 9 months
- Index test or model
- SLE-DAS compared with SLEDAI-2K for flare and improvement detection
- Target condition
- flare and clinically meaningful improvement (CMI)
Performance
As reported in the abstract
| Test or model | Sensitivity | Specificity |
|---|---|---|
| SLE-DAS | 96% | 98.9% |
| SLEDAI-2K | 84% | 98.9% |
Sensitivity
SLE-DAS96%
SLEDAI-2K84%
Specificity
SLE-DAS98.9%
SLEDAI-2K98.9%
Further findings
Clinically meaningful improvement identified (share of visits)
Correlation between SLEDAI-2K and SLE-DAS
- Spearman rho
- 0.954, 95% CI 0.934-0.968, p < 0.001
Agreement of SLEDAS remission and low disease activity (LDA) with DORIS remission and LLDAS
- Perfect agreement, κ
- 1, p < 0.001
Discordant analysis
- SLEDAI-2K underestimated severe flares and missed manifestations such as pneumonitis, AIHA, and serositis
Original publication
Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in daily clinical practice: A prospective study of 125 patients in India. Lupus. Published 29 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →